Stocks making the biggest moves midday: Moderna, ON Semiconductor, Rocket Lab, Eli Lilly, Sandisk & more

Software stocks rallied broadly, with IGV up 3% and names like ServiceNow (+8%), AppLovin (+7%), Microsoft and Salesforce (>4%) outperforming even as the wider tech sector sold off. Moderna jumped 11% after outlining a long-term mRNA oncology and rare disease strategy, while Crocs rose nearly 7% on a Piper Sandler upgrade and Robinhood gained 4% after BTIG initiated coverage at buy. Offsetting moves included ON Semiconductor's 23% drop on its planned all-stock Synaptics acquisition, weakness in memory and chipmakers, and energy stocks falling about 1% as oil prices slid 4%.

Analysis

The tape is rewarding businesses with visible path-to-monetization and penalizing hardware names tied to capex and input-cost inflation. That creates a clear intra-tech rotation: software and platform names are functioning as a relative safety trade while semis and memory are being repriced as the market pushes out the timing of AI-related demand durability and worries about margin pressure from customer concentration. The second-order implication is that investors may be de-risking the supply chain in advance of a broader “AI digestion” phase, which can persist for days to weeks even if end-demand remains intact.

The healthcare bid looks less like a one-day reaction and more like the market paying up for multi-year optionality after a period of low expectations. For Moderna, the important signal is that investors are starting to value pipeline breadth rather than just cash-flow depletion from the vaccine base; that can support multiple expansion if execution remains credible over the next 6-12 months. Elsewhere, the move in tools and large-cap pharma suggests capital is rotating toward revenue streams with lower sensitivity to macro growth and tariff/memory pass-through risk.

The ON/Synaptics reaction is the most structurally negative event in the group because it suggests the market is not rewarding scale-for-scale’s-sake M&A in semis right now. A large all-stock deal into a weak tape can be read as management acknowledging slower organic growth, and that may force peers to defend capital allocation discipline rather than pursue empire-building. Meanwhile, energy weakness is likely more of an oil-beta de-rate than a sector-specific call, but if crude stays under pressure, upstream names will face immediate estimate cuts while the bigger risk is lower buyback capacity in coming quarters.

Key Decisions for Investors

• Fade the ON/SYNA deal reaction: avoid ON on the open; if you want expression, buy SYNA or sell ON against basket strength for 1-3 weeks. Risk/reward favors further downside in ON if the market decides the acquisition is dilutive or signals growth scarcity.
• Stay long software leaders vs. semis: long MSFT/CRM/NOW basket versus short MRVL/AMD/INTC or SOXX for 5-10 trading days. The trade benefits if investors continue favoring cash-generative software and lower-duration earnings.
• Use the healthcare bid to accumulate quality on pullbacks: add VEEV and BIIB for a 3-6 month horizon, with MRNA as a higher-beta call option only if you can tolerate volatility. The setup favors multiple expansion, but MRNA should be sized smaller given execution risk.
• Short crude beta tactically: short XOM/CVX or buy puts on XLE for 1-4 weeks if oil remains under pressure. Upside in the hedge is limited, but a continued commodity drawdown can quickly compress upstream estimates and buyback expectations.
• Consider a mean-reversion long in memory after forced selling subsides: scale into WDC/STX or SNDK only after intraday stabilization, with a 2-8 week horizon. Risk/reward is attractive if Thursday’s post-earnings momentum was not fully exhausted, but respect that the tape is still risk-off.